Significance of HER2 protein examination in ductal carcinoma in situ

Journal of Surgical Research

Volumn 167, Issue 2, 2011, Pages

  Horimoto, Yoshiya ^a   Tokuda, Emi ^a   Arakawa, Atsushi ^a   Kosaka, Taijiro ^a   Saito, Mitsue ^a   Kasumi, Fujio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

biopsy; breast; carcinoma; DCIS; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER SURGERY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR BIOPSY;

ADULT; BIOPSY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79954621603     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2009.07.030     Document Type: Article

References (39)

1. P. Robbins, S. Pinder, and N. de Klerk Histological grading of breast carcinomas: A study of interobserver agreement Hum Pathol 26 1995 873
2. M.J. van de Vijver, J.L. Peterse, and W.J. Mooi Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer NEJM 319 1988 1239
3. D.M. Barnes, J. Bartkova, and R.S. Camplejohn Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 28 1992 644
4. D.C. Allred, G.M. Clark, and R. Molina Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer Hum Pathol 23 1992 974
5. R.M. Tamimi, H.J. Baer, and J. Marotti Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer Breast Cancer Res 10 2008 R67
6. M.V.M. Menezes, A.L.O. Cestari, and O. Almeida Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast Sao Paulo Med J 124 2006 121 124 (Pubitemid 44420509)
7. K. Park, S. Han, and H.J. Kim HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry Histopathology 48 2006 702
8. E.K. Latta, S. Tjan, and R.K. Parkes The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast Mod Pathol 15 2002 1318
9. G.H. Ho, J.E. Calvano, and M. Bisogna In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology Cancer 89 2000 2153
10. A. Hoque, N. Sneige, and A.A. Sahin HER-2/neu gene amplification in ductal carcinoma in situ of the breast Cancer Epidemiol Biomarkers Prev 11 2002 587
11. H. Schimmelpenning, E.T. Eriksson, and L. Pallis Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ Am J Clin Pathol 97 1992 48
12. A. Lebeau, A. Unholzer, and G. Amann EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast Breast Cancer Res Treat 79 2003 187
13. G.D. Leonard, and S.M. Swain Ductal carcinoma in situ, complexities and challenges J Natl Cancer Inst 96 2004 906
14. F. Warnberg, H. Nordgren, and L. Bergkvisit Tumor markers in breast carcinoma correlate with grade rather than with invasiveness Br J Cancer 85 2001 869
15. M.D. Lagios Duct carcinoma in situ: Biological implications for clinical practice Semin Oncol 23 1996 6
16. S.A. Silver, and F.A. Tavassoli Mammary ductal carcinoma in situ with microinvasion Cancer 82 1998 2382
17. M.J. Silverstein, J.R. Waisman, and P. Gamagami Intraductal carcinoma of the breastv Cancer 66 1990 102
18. M.D. Lagios, F.R. Margolin, and P.R. Westdahl Mammographically detected duct carcinoma in situ Cancer 63 1989 618
19. C.O. Bellamy, C. McDonald, and D.M. Salter Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization Hum Pathol 24 1993 16
20. E.R. Fisher, J. Dignam, and E. Tan-Chiu Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17 Cancer 86 1999 429
21. B. Erbas, E. Provenzano, and J. Armes The natural history of ductal carcinoma in situ of the breast Breast Cancer Res Treat 97 2006 135
22. M.J. van de Vijver Biological variables and prognosis of DCIS Breast 14 2005 509
23. S. Steinman, J. Wang, and P. Bourne Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with coexisting invasive ductal carcinoma (IDC) of the breast Ann Clin Lab Sci 37 2007 127
24. P. Meijnen, J.L. Peterse, and N. Antonini Immunohistochemical categorization of ductal carcinoma in situ of the breast Br J Cancer 98 2008 137
25. M.E. Sanders, P.A. Schuyler, and W.D. Dupont The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up Cancer 103 2005 2481
26. J.W. Lee, W. Han, and E. Ko Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus J Surg Oncol 98 2008 15
27. M.F. Dillon, E.W. McDermott, and C.M. Quinn Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only J Surg Oncol 93 2006 559
28. T.W.F. Yen, K.K. Hunt, and M.I. Ross Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ J Am Coll Surg 200 2005 516
29. L.E. Hoorntje, M.E. Schipper, and P.H. Peeters The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma- in situ: Causes of ductal carcinoma- in situ underestimates with stereotactic 14-gauge needle biopsy Ann Surg Oncol 10 2003 748
30. M.J. Bagnall, A.J. Evans, and A.R.M. Wilson Predicting invasion in mammographically detected microcalcification Clin Radiol 56 2001 828
31. R.E. Roses, E.C. Paulson, and A. Sharma HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer Cancer Epidemiol Biomarkers Prev 18 2009 1386
32. M. Yang, T. Moriya, and M. Oguma Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases Pathol Int 53 2003 422
33. M. Yi, S. Krishnamurthy, and H.M. Kuerer Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer Am J Surg 196 2008 81
34. M. Wu, L. Jung, and A.B. Cooper Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice Proc Natl Acad Sci U S A 106 2009 7022
35. N. Bijker, J.L. Peterse, and L. Duchateau Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma- in situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853 J Clin Oncol 19 2001 2263
36. E. Provenzano, J.L. Hooper, and G.G. Giles Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast Eur J Cancer 39 2003 622
37. D.B. Cornfield, J.P. Palazzo, and G.F. Schwartz The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast Cancer 100 2004 2317
38. A. Ringberg, L. Anagnostaki, and H. Anderson Cell biological factors in ductal carcinoma in situ (DCIS) of the breast - relationship to ipsilateral local recurrence and histopathological characteristics Eur J Cancer 37 2001 1514
39. R.R. Millis, K. Ryder, and I.S. Fentiman Ductal in situ component and prognosis in invasive mammary carcinoma Breast Cancer Treat 84 2004 197